EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study

Evan S Dellon, David A Katzka, Vincent A Mukkada, Margaret H Collins, Gary W Falk, Camilla A Richmond, Brian Terreri, Manoj Thakur, Mena Boules, Bridgett Goodwin, Ikuo Hirano

Clinical Gastroenterology and Hepatology · 2025-11 · 23 (12) · 2155-2166.e5

DOI: 10.1016/j.cgh.2024.12.024 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-11. Verfasst von Evan S Dellon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at C…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Budesonide, Anti-Inflammatory Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals USA Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: We investigated the long-term safety and efficacy of budesonide oral suspension (BOS) in eosinophilic esophagitis (EoE). METHODS: This study (SHP621-303) was a 4-year, phase 3, open-label study in patients with EoE who completed up to 52 weeks of BOS therapy in 2 preceding phase 3 studies. On the basis of treatment assignments in previous studies, patients were assigned to BOS-BOS or placebo-BOS groups. All patients received BOS 2.0 mg twice daily; dose reductions to once daily and interruptions were permitted. The safety and tolerability of BOS were primarily investigated, with exploratory efficacy endpoints also examined. RESULTS: Overall, 131 patients were included. BOS was well-tolerated, with no unexpected safety signals observed. Treatment-emergent adverse events (TEAEs) occurred in 76.3% of patients; most were mild/moderate in severity and unrelated to study drug. The most frequently reported BOS-related TEAEs included abnormal adrenocorticotropic hormone stimulation test results (8.4%, 11/131; number of events [m] = 12) and adrenal insufficiency (2.3%, 3/131; m = 3). Esophageal candidiasis occurred in 3.1% of patients (4/131). The aforementioned TEAEs resolved in most patients. At month 48 of treatment, 50.0% and 58.3% of patients achieved/maintained a histologic response (≤6 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisBudesonideAnti-Inflammatory AgentsHumansMaleFemaleAdultTreatment OutcomeMiddle AgedAdministration, OralSuspensionsYoung AdultAdolescentPlacebosAgedDrug-Related Side Effects and Adverse ReactionsChild

Stichwörter der Autor:innen

Budesonide Oral SuspensionEosinophilic EsophagitisLong-Term EfficacyLong-Term Safety

Substanzen

BudesonideSuspensionsPlacebosAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: evan_dell…
  • Division of Digestive and Liver Diseases, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Division of Pathology and Laboratory Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cinc…
  • Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Takeda Development Center Americas, Inc, Cambridge, Massachusetts.

Förderung

  • Takeda Pharmaceuticals USA Inc

Zitieren

APA

Dellon, E. S., Katzka, D. A., Mukkada, V. A., Collins, M. H., Falk, G. W., Richmond, C. A., Terreri, B., Thakur, M., Boules, M., Goodwin, B., & Hirano, I. (2025). Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study. Clinical Gastroenterology and Hepatology, 23(12), 2155-2166.e5. https://doi.org/10.1016/j.cgh.2024.12.024

Vancouver

Dellon ES, Katzka DA, Mukkada VA, Collins MH, Falk GW, Richmond CA, et al. Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study. Clinical Gastroenterology and Hepatology. 2025;23(12):2155-2166.e5. doi:10.1016/j.cgh.2024.12.024

BibTeX
@article{Dellon2025,
  author = {Dellon, Evan S and Katzka, David A and Mukkada, Vincent A and Collins, Margaret H and Falk, Gary W and Richmond, Camilla A and Terreri, Brian and Thakur, Manoj and Boules, Mena and Goodwin, Bridgett and Hirano, Ikuo},
  title = {Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  volume = {23},
  number = {12},
  pages = {2155--2166.e5},
  doi = {10.1016/j.cgh.2024.12.024}
}
Kostenlos starten →